Covered recipient · General Payments record
CINDY E OWEN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,269.36
78 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,269.36 | 78 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $295.59 | 23 |
| Novartis Pharmaceuticals Corporation | $275.69 | 21 |
| Arcutis Biotherapeutics, Inc. | $142.79 | 12 |
| Kyowa Kirin, Inc. | $119.70 | 1 |
| Lilly USA, LLC | $114.91 | 6 |
| Regeneron Healthcare Solutions, Inc. | $107.40 | 5 |
| LEO Pharma Inc. | $84.02 | 4 |
| Incyte Corporation | $40.18 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.57 | 1 |
| Paratek Pharmaceuticals, Inc. | $23.81 | 1 |
| Galderma Laboratories, L.P. | $22.12 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $13.58 | 1 |
Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CINDY E OWEN
NPI 1598803819 · CMS profile ID 117868
Allopathic & Osteopathic Physicians / Dermatology
LOUISVILLE, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1598803819?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
78 matching records · $1,269.36 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 78.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $6.34 | 12/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164215 | CMS |
| Lilly USA, LLC | $16.42 | 12/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136124283 | CMS |
| ABBVIE INC. | $26.70 | 12/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164213 | CMS |
| Regeneron Healthcare Solutions, Inc. | $33.77 | 12/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114129008 | CMS |
| Novartis Pharmaceuticals Corporation | $1.28 | 12/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284165 | CMS |
| Galderma Laboratories, L.P. | $22.12 | 11/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145320037 | CMS |
| ABBVIE INC. | $27.11 | 11/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164211 | CMS |
| ABBVIE INC. | $13.19 | 11/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164209 | CMS |
| Novartis Pharmaceuticals Corporation | $20.81 | 10/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284163 | CMS |
| Lilly USA, LLC | $22.31 | 10/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136106507 | CMS |
| Novartis Pharmaceuticals Corporation | $8.19 | 10/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284155 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.31 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114129006 | CMS |
| Arcutis Biotherapeutics, Inc. | $5.13 | 10/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040756 | CMS |
| Novartis Pharmaceuticals Corporation | $2.30 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284151 | CMS |
| Arcutis Biotherapeutics, Inc. | $19.69 | 10/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040754 | CMS |
| Novartis Pharmaceuticals Corporation | $22.81 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284149 | CMS |
| ABBVIE INC. | $4.86 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164207 | CMS |
| Arcutis Biotherapeutics, Inc. | $5.05 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040746 | CMS |
| ABBVIE INC. | $14.52 | 09/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164205 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $13.58 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153807089 | CMS |
| Arcutis Biotherapeutics, Inc. | $7.40 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040750 | CMS |
| Novartis Pharmaceuticals Corporation | $0.92 | 08/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284135 | CMS |
| Novartis Pharmaceuticals Corporation | $7.98 | 08/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284139 | CMS |
| Novartis Pharmaceuticals Corporation | $18.12 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284131 | CMS |
| ABBVIE INC. | $18.82 | 08/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164203 | CMS |
| Arcutis Biotherapeutics, Inc. | $19.69 | 08/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040744 | CMS |
| Arcutis Biotherapeutics, Inc. | $2.84 | 08/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040748 | CMS |
| Lilly USA, LLC | $19.87 | 08/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136128105 | CMS |
| ABBVIE INC. | $8.78 | 07/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164201 | CMS |
| Regeneron Healthcare Solutions, Inc. | $13.16 | 07/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114129004 | CMS |
| LEO Pharma Inc. | $19.55 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152645263 | CMS |
| Novartis Pharmaceuticals Corporation | $18.12 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284129 | CMS |
| Novartis Pharmaceuticals Corporation | $26.71 | 07/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284125 | CMS |
| Novartis Pharmaceuticals Corporation | $23.09 | 07/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284157 | CMS |
| Arcutis Biotherapeutics, Inc. | $16.06 | 07/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040752 | CMS |
| Lilly USA, LLC | $22.87 | 06/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136103534 | CMS |
| Arcutis Biotherapeutics, Inc. | $18.17 | 06/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040738 | CMS |
| ABBVIE INC. | $10.84 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164199 | CMS |
| Novartis Pharmaceuticals Corporation | $1.28 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284121 | CMS |
| Novartis Pharmaceuticals Corporation | $5.08 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284115 | CMS |
| Novartis Pharmaceuticals Corporation | $15.94 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284111 | CMS |
| ABBVIE INC. | $5.81 | 06/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164197 | CMS |
| Paratek Pharmaceuticals, Inc. | $23.81 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 1113912973 | CMS |
| Novartis Pharmaceuticals Corporation | $6.40 | 05/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284113 | CMS |
| ABBVIE INC. | $3.62 | 05/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164195 | CMS |
| ABBVIE INC. | $16.18 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105164193 | CMS |
| Lilly USA, LLC | $26.29 | 05/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136103536 | CMS |
| Arcutis Biotherapeutics, Inc. | $4.79 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121040740 | CMS |
| Kyowa Kirin, Inc. | $119.70 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127027713 | CMS |
| Novartis Pharmaceuticals Corporation | $18.95 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087284109 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $848,779.58 | 205 |
| PY2024 | Principal investigator | $465,404.25 | 284 |
| PY2023 | Principal investigator | $512,761.61 | 145 |
| PY2022 | Recipient | $8.00 | 1 |
| PY2022 | Principal investigator | $318,333.10 | 76 |
| PY2021 | Recipient | $579.11 | 2 |
| PY2021 | Principal investigator | $303,603.63 | 109 |
| PY2020 | Recipient | $5,811.05 | 7 |
| PY2020 | Principal investigator | $509,738.55 | 72 |
| PY2019 | Recipient | $47,562.83 | 13 |
| PY2019 | Principal investigator | $1,244,974.63 | 84 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
97 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Amgen Inc. | $1,547.00 | 12/24/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DS RESEARCH | Phase 2b study of Tezepelumab in Atopic Dermatitis. | No dispute reported | 06/30/2026 | 675778161 |
| Principal investigator 1 | AbbVie, Inc. | $9,261.00 | 12/19/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M15-999 | No dispute reported | 06/30/2026 | 647568217 |
| Principal investigator 1 | Genentech, Inc. | $16,484.00 | 12/02/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | PHII OF MSTT1041A IN MOD SEVERE ATOPIC DERMATITITS | No dispute reported | 06/30/2026 | 708836475 |
| Principal investigator 1 | AbbVie, Inc. | $4,159.75 | 11/27/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568223 |
| Principal investigator 1 | PFIZER INC. | $4,952.48 | 11/22/2019 | Non-covered Recipient Entity DS Research | PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS | No dispute reported | 06/30/2026 | 671666047 |
| Principal investigator 1 | AbbVie, Inc. | $6,054.00 | 11/21/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M15-999 | No dispute reported | 06/30/2026 | 647568215 |
| Recipient | Eli Lilly and Company | $2,385.84 | 11/21/2019 | Covered Recipient Physician | A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | No dispute reported | 06/30/2026 | 654281571 |
| Recipient | Eli Lilly and Company | $2,464.20 | 11/21/2019 | Covered Recipient Physician | A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654281831 |
| Principal investigator 1 | Eli Lilly and Company | $200.00 | 11/18/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | No dispute reported | 06/30/2026 | 654289805 |
| Principal investigator 1 | AbbVie, Inc. | $929.25 | 10/31/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568219 |
| Principal investigator 1 | Incyte Corporation | $66,583.62 | 10/22/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516043 |
| Principal investigator 1 | AbbVie, Inc. | $7,870.75 | 10/21/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M15-999 | No dispute reported | 06/30/2026 | 647568209 |
| Principal investigator 1 | AbbVie, Inc. | $11,256.00 | 10/02/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568221 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $1,920.00 | 09/26/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700990215 |
| Principal investigator 1 | AbbVie, Inc. | $13,639.00 | 09/19/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M15-999 | No dispute reported | 06/30/2026 | 647568207 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,437.20 | 09/10/2019 | Non-covered Recipient Entity Associates In Dermatology Dispensar | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 639759343 |
| Principal investigator 1 | Perrigo Company plc | $34,390.00 | 09/05/2019 | Non-covered Recipient Entity Scott Health Services, LLC | Bioequivalence study between Perrigo's product and Epiduo Forte Gel | No dispute reported | 06/30/2026 | 669993641 |
| Principal investigator 1 | AbbVie, Inc. | $4,912.75 | 09/04/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M15-999 | No dispute reported | 06/30/2026 | 647568205 |
| Principal investigator 1 | AbbVie, Inc. | $12,851.50 | 08/29/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568211 |
| Principal investigator 1 | PFIZER INC. | $3,500.00 | 08/27/2019 | Non-covered Recipient Entity DS Research | PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS | No dispute reported | 06/30/2026 | 671666043 |
| Principal investigator 1 | PFIZER INC. | $3,500.00 | 08/27/2019 | Non-covered Recipient Entity DS Research | PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS | No dispute reported | 06/30/2026 | 671666045 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $1,800.00 | 08/22/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700989911 |
| Principal investigator 1 | Amgen Inc. | $13.12 | 08/22/2019 | Non-covered Recipient Entity DS RESEARCH | P3 KRd QW vs BIW Dosing Comparison in RRMM (A.R.R.O.W. 2) | No dispute reported | 06/30/2026 | 675785255 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,019.40 | 08/12/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES, LLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701426383 |
| Principal investigator 1 | Eli Lilly and Company | $1,102.80 | 08/08/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654296307 |
| Recipient | Bausch Health US, LLC | $1,500.00 | 08/05/2019 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 684338318 |
| Recipient | Bausch Health US, LLC | $1,500.00 | 08/05/2019 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 684338321 |
| Principal investigator 1 | AbbVie, Inc. | $10,934.00 | 08/01/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568213 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $3,120.00 | 08/01/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700989627 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $8,960.00 | 06/25/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700989219 |
| Principal investigator 1 | Amgen Inc. | $11,396.00 | 06/25/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DS RESEARCH | Phase 2b study of Tezepelumab in Atopic Dermatitis. | No dispute reported | 06/30/2026 | 675792227 |
| Principal investigator 1 | PFIZER INC. | $521.23 | 06/20/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS | No dispute reported | 06/30/2026 | 671657791 |
| Principal investigator 1 | AbbVie, Inc. | $20,984.25 | 06/13/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568203 |
| Principal investigator 1 | Amgen Inc. | $1,999.76 | 05/28/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | Phase 2b study of Tezepelumab in Atopic Dermatitis. | No dispute reported | 06/30/2026 | 675792203 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $15,760.00 | 05/23/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700988533 |
| Principal investigator 1 | Incyte Corporation | $6,202.98 | 05/21/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666515959 |
| Principal investigator 1 | PFIZER INC. | $691.28 | 05/07/2019 | Non-covered Recipient Entity Scott Health Services LLC dba DS Research | A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671655231 |
| Principal investigator 1 | AbbVie, Inc. | $9,001.50 | 05/03/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568201 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $23,050.00 | 04/25/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700988153 |
| Principal investigator 1 | Amgen Inc. | $947.06 | 04/25/2019 | Non-covered Recipient Entity DS RESEARCH KENTUCKY | Phase 2b study of Tezepelumab in Atopic Dermatitis. | No dispute reported | 06/30/2026 | 675785261 |
| Principal investigator 1 | Eli Lilly and Company | $23.57 | 04/25/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654295643 |
| Principal investigator 1 | Perrigo Company plc | $19,965.00 | 04/23/2019 | Non-covered Recipient Entity Scott Health Services, LLC | Bioequivalence study between Perrigo's product and Epiduo Forte Gel | No dispute reported | 06/30/2026 | 669976999 |
| Principal investigator 1 | Perrigo Company plc | $6,926.30 | 04/16/2019 | Non-covered Recipient Entity Scott Health Services, LLC | Bioequivalence study between Perrigo's product and Epiduo Forte Gel | No dispute reported | 06/30/2026 | 669976959 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $3,250.00 | 04/09/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700987887 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $3,000.00 | 04/08/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES, LLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701426331 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $4,640.00 | 04/08/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES, LLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701426333 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $500.00 | 04/08/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES, LLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701426349 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $5,000.00 | 04/05/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700987859 |
| Principal investigator 1 | AbbVie, Inc. | $11,411.25 | 04/03/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568231 |
| Principal investigator 1 | PFIZER INC. | $322.30 | 03/22/2019 | Non-covered Recipient Entity Scott Health Services LLC dba DS Research | A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671657993 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $9,970.00 | 03/19/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700987615 |
| Principal investigator 1 | Eli Lilly and Company | $41,838.00 | 03/19/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654297299 |
| Recipient | Eli Lilly and Company | $17.44 | 03/14/2019 | Covered Recipient Physician | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654281829 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $17,620.00 | 03/05/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700987321 |
| Principal investigator 1 | Eli Lilly and Company | $33,694.00 | 03/05/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654294375 |
| Principal investigator 1 | AbbVie, Inc. | $11,758.00 | 03/01/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568227 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666515929 |
| Principal investigator 1 | Incyte Corporation | $1,400.00 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666515931 |
| Principal investigator 1 | Incyte Corporation | $481.10 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516089 |
| Principal investigator 1 | Incyte Corporation | $96.24 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516091 |
| Principal investigator 1 | Incyte Corporation | $292.70 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516095 |
| Principal investigator 1 | Incyte Corporation | $103.36 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516099 |
| Principal investigator 1 | Incyte Corporation | $124.40 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516105 |
| Principal investigator 1 | Incyte Corporation | $216.13 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516111 |
| Principal investigator 1 | Incyte Corporation | $108.03 | 03/01/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS PSC | TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666516119 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $3,250.00 | 02/26/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700986959 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $5,000.00 | 02/26/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700986991 |
| Recipient | Eli Lilly and Company | $8,190.00 | 02/26/2019 | Covered Recipient Physician | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654281631 |
| Recipient | Eli Lilly and Company | $2,848.00 | 02/26/2019 | Covered Recipient Physician | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654281717 |
| Recipient | Eli Lilly and Company | $1,378.00 | 02/26/2019 | Covered Recipient Physician | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 654281783 |
| Recipient | Eli Lilly and Company | $862.10 | 02/25/2019 | Covered Recipient Physician | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 654281523 |
| Principal investigator 1 | Eli Lilly and Company | $22.36 | 02/21/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654292753 |
| Principal investigator 1 | PFIZER INC. | $322.30 | 02/19/2019 | Non-covered Recipient Entity Scott Health Services LLC dba DS Research | A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671657629 |
| Principal investigator 1 | Eli Lilly and Company | $38,021.00 | 02/12/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654291471 |
| Principal investigator 1 | Eli Lilly and Company | $34,972.00 | 02/12/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | No dispute reported | 06/30/2026 | 654292533 |
| Principal investigator 1 | Eli Lilly and Company | $117,312.00 | 02/12/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654293407 |
| Principal investigator 1 | Perrigo Company plc | $16,150.00 | 02/08/2019 | Non-covered Recipient Entity Scott Health Services, LLC | Bioequivalence study between Perrigo's product and Epiduo Forte Gel | No dispute reported | 06/30/2026 | 669953219 |
| Principal investigator 1 | Amgen Inc. | $2,672.50 | 02/05/2019 | Non-covered Recipient Entity DS RESEARCH | Phase 2b study of Tezepelumab in Atopic Dermatitis. | No dispute reported | 06/30/2026 | 675785259 |
| Principal investigator 1 | Eli Lilly and Company | $128,472.00 | 02/05/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654297297 |
| Principal investigator 1 | PFIZER INC. | $951.29 | 02/05/2019 | Non-covered Recipient Entity Scott Health Services LLC dba DS Research | A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671658027 |
| Principal investigator 1 | AbbVie, Inc. | $12,748.25 | 02/04/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568225 |
| Principal investigator 1 | Amgen Inc. | $2,755.85 | 01/28/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | Phase 2b study of Tezepelumab in Atopic Dermatitis. | No dispute reported | 06/30/2026 | 675792211 |
| Recipient | Eli Lilly and Company | $870.25 | 01/28/2019 | Covered Recipient Physician | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654281833 |
| Principal investigator 1 | Eli Lilly and Company | $1,713.85 | 01/28/2019 | Non-covered Recipient Entity ARTHRITIS CONSULTANTS INC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654287983 |
| Principal investigator 1 | Eli Lilly and Company | $793.33 | 01/28/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654291819 |
| Principal investigator 1 | Eli Lilly and Company | $802.80 | 01/28/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654295645 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $19,220.00 | 01/22/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700986713 |
| Principal investigator 1 | PFIZER INC. | $1,543.71 | 01/19/2019 | Non-covered Recipient Entity Scott Health Services LLC dba DS Research | A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671655075 |
| Recipient | Eli Lilly and Company | $5,382.00 | 01/15/2019 | Covered Recipient Physician | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654281525 |
| Recipient | Eli Lilly and Company | $12,180.00 | 01/15/2019 | Covered Recipient Physician | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 654281921 |
| Recipient | Eli Lilly and Company | $7,985.00 | 01/08/2019 | Covered Recipient Physician | A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 654281573 |
| Principal investigator 1 | AbbVie, Inc. | $10,857.50 | 01/07/2019 | Non-covered Recipient Entity Scott Health Services, LLC | M16-766 | No dispute reported | 06/30/2026 | 647568229 |
| Principal investigator 1 | PFIZER INC. | $2,485.45 | 01/04/2019 | Non-covered Recipient Entity Scott Health Services LLC dba DS Research | A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671654931 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $5,810.00 | 01/03/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | No dispute reported | 06/30/2026 | 700986431 |
| Principal investigator 1 | Celgene Corporation | $15,155.00 | 01/03/2019 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) | No dispute reported | 06/30/2026 | 675418873 |
| Principal investigator 1 | Eli Lilly and Company | $799.94 | 01/03/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654293709 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $316,451.44 | 01/02/2019 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESESARCH | A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS | No dispute reported | 06/30/2026 | 640715117 |